Royalty Pharma stock price target raised to $38 from $37 at UBS

Royalty Pharma (RPRX) has seen mixed analyst sentiment despite strong financial performance and strategic acquisitions. UBS raised its price target to $38.00 from $37.00, based on an increased 2026 EBITDA estimate of $3.06 billion reflecting new royalty deals, but maintained a Neutral rating due to perceived "structural issues in the equity story." Conversely, BofA Securities increased its price target to $48 from $42 with a Buy rating, following robust Q2 results and the company's $885 million acquisition of a royalty interest in Amgen’s Imdelltra. The stock has delivered a 40.48% year-to-date return, with TD Cowen also reiterating a Buy rating.

Analysis

Royalty Pharma (RPRX) presents a case of strong fundamental performance contrasted with divergent analyst sentiment. The company reported robust second-quarter results, with portfolio receipts of $727 million surpassing consensus estimates by 6%, driven by mature products and new launches such as Rytelo and Skytrofa. This operational strength is complemented by strategic capital deployment, highlighted by the $885 million upfront acquisition of a royalty interest in Amgen's Imdelltra. In response, BofA Securities raised its price target to $48, maintaining a Buy rating, and TD Cowen reiterated its Buy. However, UBS, while lifting its price target to $38 from $37, maintained a Neutral rating due to perceived "structural issues in the equity story," even as it acknowledged strong business fundamentals. The UBS target is based on a 10x EV/EBITDA multiple applied to a slightly increased 2026 EBITDA estimate of $3.06 billion, which now incorporates new deals. Despite the caution from UBS, the stock has returned 40.48% year-to-date and trades at an attractive PEG ratio of 0.27, suggesting potential undervaluation relative to its growth, a view supported by its 'GREAT' financial health score from InvestingPro.

Key Decisions for Investors

• Investors should weigh the company's strong operational momentum and bullish ratings from BofA and TD Cowen against the unspecified 'structural issues' cited by UBS, which create a significant valuation discrepancy between analyst targets ($38 vs $48).
• Given the attractive PEG ratio of 0.27 and strong financial health metrics, the stock may appeal to growth-at-a-reasonable-price (GARP) investors, particularly as recent accretive royalty acquisitions begin to flow into forward estimates.
• It is prudent to monitor future management commentary and analyst reports for clarification on the 'structural issues' flagged by UBS, as resolution of this point could serve as a major catalyst or headwind for the stock.
• Note the recent change in corporate governance with the departure of the Lead Independent Director, which warrants observation for any potential shifts in board strategy or oversight.